Logica

Logica is a groundbreaking AI-enhanced small molecule drug discovery platform formed through a strategic collaboration between Charles River and Valo Health. By uniting Charles River's decades of industry-leading drug discovery, data generation, and experimental expertise with Valo Health's revolutionary Opal Computational Platform™, Logica delivers a comprehensive, fully managed drug discovery solution designed to transform targets into preclinical candidates with greater speed, certainty, and predictability.

Logica serves biopharmaceutical and life sciences organizations seeking to accelerate their small molecule programs from target identification through to candidate nomination. The platform operates on a distinctive risk-sharing business model that provides clients with a fixed budget upfront tied to key value-inflection points — eliminating hidden costs and unreliable timelines. This model aligns Logica's success directly with the client's outcomes, embodying the principle of our risk, your reward.

Core Platform Deliverables

• Hit Identification (Logica-A): Rapid model builds and virtual screening, bolstered by DNA-encoded library (DEL) screening or rapid high-throughput screening (HTS) as needed to identify promising starting points.
• Lead Optimization (Logica-B): De-risking lead molecules through pharmacokinetic (PK) studies and in vivo target engagement studies to build confidence in lead series advancement.
• Candidate Delivery (Logica-C): Generation of a high-quality, de-risked drug candidate asset that is decision-ready for IND planning.

Key Capabilities and Technology

• Leading-edge AI and machine learning (ML) integrated natively with full-service drug discovery expertise to accelerate innovation.
• Access to hundreds of in vitro and in vivo models and thousands of computational predictive models enabling rapid advancement to candidate selection.
• Virtual advanceability assessment coupled with empirical measurements, achieving a reported 90% success rate in generating viable and advanceable lead series.
• A closed-loop discovery system that amalgamates molecular design and biological assay data to iteratively construct high-precision predictive models.
• The ability to scan billions of virtual molecules per cycle, rapidly iterating through a broad universe of actionable chemistry to rank and deliver novel chemistries.
• Virtual and physical high-throughput hit-finding capabilities, including DNA-encoded libraries (DEL).
• Human drug discovery expertise kept at the epicenter of all AI-driven decision-making.

Partnership and Team

• Logica is led by a multidisciplinary team drawing from both Charles River and Valo Health, including experts in strategic commercial development, scientific portfolio management, scientific operations, project leadership, computational technology, and program management.
• Notable team members include Dr. Sneha Kumar (Strategic Commercial Lead), Alison Jones, Ph.D. (Scientific Portfolio Lead), Grant Wishart, Ph.D. (Scientific Operations Lead), John Ellard, Ph.D. (Project Lead), Guido Lanza, MSc (Chief Technology Officer, from Valo Health), and Kristopher King, MBA (Scientific Liaison and Project Leader).

Mission, Vision, and Notable Achievements

• Logica's joint mission is to remove at least one year from the drug discovery and development timeline by accelerating the identification and optimization of promising drug candidates.
• The platform keeps the patient at the center of all activities and aspires to deliver exceptional research across any modality and therapeutic area.
• Logica has demonstrated real-world impact, including identifying a potential therapeutic for lupus and entering a collaboration with Lundbeck to advance the discovery of novel drugs for neurological disease.
• Clients can engage with any single phase or combine sequential phases of the platform, with the flexibility to enter or exit at any point in the process.

Logica represents a convergence of scientific excellence and AI innovation purpose-built for small molecule drug discovery, offering pharmaceutical and biotech partners a single, trusted partner to navigate the full journey from target biology through compound optimization to candidate nomination.